V. Shi

CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

G. Lenz, K. Ardeshna, B. Childs, 2017 .

Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND).

S. Shumack, G. Chan, H. Valdez, 2022, Journal of the American Academy of Dermatology.

Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

G. Salles, G. Lenz, K. Ardeshna, 2017 .